An Overview of Chemotherapy-Induced Peripheral Neuropathy
| Autor: | Michael S. Oholendt, James E. Cox, Jose R. Murillo |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Chemotherapy
business.industry medicine.medical_treatment Central nervous system Neurotoxicity Pharmacology Bioinformatics medicine.disease medicine.anatomical_structure Peripheral neuropathy Chemotherapy-induced peripheral neuropathy Peripheral nervous system Toxicity medicine Pharmacology (medical) business Adverse effect |
| Zdroj: | Journal of Pharmacy Practice. 21:138-145 |
| ISSN: | 1531-1937 0897-1900 |
| DOI: | 10.1177/0897190008315056 |
| Popis: | Peripheral nervous system (PNS) toxicity is a common and potentially serious adverse effect of several different systemic chemotherapeutic agents. The central nervous system (CNS) is protected from exposure to toxic agents by the tight junctions of endothelial cells separating blood from cerebrospinal fluid (CSF), the blood–brain barrier (BBB). The BBB is responsible for regulating the movement of substance from extracellular fluids within the body and the brain, as well as for protecting the brain from hydrophilic agents like chemotherapy. Because the BBB does not protect peripheral nerves, PNS toxicity is more common than CNS toxicity. Consequences of peripheral neuropathy (PN) can include interruption and delays in therapy, complete discontinuation of future treatments, or significant impairment in a patient’s quality of life. Individual patient responses to therapy present variable risks for the development of PN. As such, it is sometimes Peripheral neuropathy remains a major limitation of chemotherapeutic agents used in cancer treatment. This neurologic complication from chemotherapy occurs frequently and can be debilitating. Although difficult to predict, both chemotherapeutic and patient-specific risk factors may contribute to this adverse event. Symptoms of peripheral neuropathy may appear acutely after treatment or persist chronically upon drug discontinuation. The taxanes, vinca alkaloids, and immunomodulatory drugs commonly cause peripheral nervous system toxicity. Prompt recognition and evaluation of this neurological adverse event by those who provide care to patients with cancer can prove to have a positive impact on the quality of life of those patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|